Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beat Roth

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Clinical Kidney Journal|May 18, 2026
Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effectsAlexander Ritter, Lea Bührer, Daniel G Fuster, et al.
Molecular Cancer Research : MCR|March 4, 2020
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder CancerSharada Mokkapati, Sima P Porten, Vikram M Narayan, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|April 29, 2023
Differences in the Food Consumption Between Kidney Stone Formers and Nonformers in the Swiss Kidney Stone CohortConstance Legay, Tanja Haeusermann, Jérôme Pasquier, et al.
European Urology Open Science|October 10, 2022
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety ProfileIlaria Lucca, Laurent Derré, Valérie Cesson, et al.
Frontiers in Immunology|November 28, 2025
Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patientsWalther Brochier, Sylvain Nguyen, Valérie Cesson, et al.
Revue Medicale Suisse|December 1, 2021
[Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]Caroline Codeluppi, Françoise Ninane, Laura Jolliet, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potentialLaurent Derré, Ilaria Lucca, Valérie Cesson, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Cancers|June 28, 2023
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate CancerRitaparna Ahmed, Leyder Elena Lozano, Amandine Anastasio, et al.
European Urology Oncology|January 11, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14Cyrill A Rentsch, George N Thalmann, Ilaria Lucca, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Clinical Kidney Journal|May 18, 2026
Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effectsAlexander Ritter, Lea Bührer, Daniel G Fuster, et al.
Molecular Cancer Research : MCR|March 4, 2020
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder CancerSharada Mokkapati, Sima P Porten, Vikram M Narayan, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|April 29, 2023
Differences in the Food Consumption Between Kidney Stone Formers and Nonformers in the Swiss Kidney Stone CohortConstance Legay, Tanja Haeusermann, Jérôme Pasquier, et al.
European Urology Open Science|October 10, 2022
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety ProfileIlaria Lucca, Laurent Derré, Valérie Cesson, et al.
Frontiers in Immunology|November 28, 2025
Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patientsWalther Brochier, Sylvain Nguyen, Valérie Cesson, et al.
Revue Medicale Suisse|December 1, 2021
[Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]Caroline Codeluppi, Françoise Ninane, Laura Jolliet, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potentialLaurent Derré, Ilaria Lucca, Valérie Cesson, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Cancers|June 28, 2023
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate CancerRitaparna Ahmed, Leyder Elena Lozano, Amandine Anastasio, et al.
European Urology Oncology|January 11, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14Cyrill A Rentsch, George N Thalmann, Ilaria Lucca, et al.
Pageof 14